SCHEMBL3104864

SCHEMBL3104864

NCCNc1n[nH]c2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.48
GAA P10253 2/20 0.48
PDPK1 O15530 1/20 0.48
CYP3A4 P08684 1/20 0.48
TRPA1 O75762 1/20 0.47
ACHE P22303 1/20 0.45
FADS1 O60427 2/20 0.44
ADRA2A P08913 2/20 0.44
MAPK10 P53779 8/20 0.44
MAPK8 P45983 5/20 0.44
ILK Q13418 1/20 0.43
ROCK2 O75116 1/20 0.42
ROCK1 Q13464 1/20 0.42
PKN2 Q16513 1/20 0.42
CA12 O43570 1/20 0.42
CA3 P07451 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3243994 0.83 UTS2R (0.52) KDM4EGAAPDPK1CYP3A4TRPA1
SCHEMBL1662606 0.79 UTS2R (0.56) KDM4ECYP3A4TRPA1ACHEFADS1
SCHEMBL10831906 0.79 GAA (0.51) GAATRPA1ACHEADRA2AILK
SCHEMBL19505620 0.79 TRPA1 (0.50) KDM4EGAAPDPK1CYP3A4TRPA1
SCHEMBL700943 0.79 TRPA1 (0.50) KDM4EGAAPDPK1CYP3A4TRPA1
SCHEMBL13996487 0.79 UTS2R (0.50) KDM4EGAAPDPK1CYP3A4TRPA1
SCHEMBL2564238 0.78 CHEK1 (0.35) ILKROCK2ROCK1PKN2
SCHEMBL1274224 0.77 MAPK10 (0.61) ACHEMAPK10MAPK8
SCHEMBL11087609 0.76 TOP2A (0.52) KDM4EGAAADRA2AILKALDH1A1
SCHEMBL11700794 0.76 KDM4E (0.57) KDM4EGAAPDPK1CYP3A4TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2198867-A1 Pyrimidine-based compounds useful as GSK-3 inhibitors Vertex Pharmaceuticals, Inc. (US) 2010-06-23 EP disclosed
EP-1474147-B1 PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS VERTEX PHARMA (US) 2010-05-05 EP disclosed
EP-1474147-A1 PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2004-11-10 EP disclosed
US-20030199526-A1 Pyrimidine-based compounds useful as GSK-3 inhibitors VERTEX PHARMACEUTICALS, INCORPORATED 2003-10-23 US disclosed
WO-2003049739-A1 PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS VERTEX PHARMACEUTICALS, INC. (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199526-A1 Pyrimidine-based compounds useful as GSK-3 inhibitors GSK3B, GSK3A, GSKIP KDM4E 1477/4885GAA 2040/4885PDPK1 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.